Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.

Kunal Desai,Landon Carter Brown,Wei Wei,Kimberly D Allman,Allison Martin,Laura S. Wood,Shilpa Gupta,Timothy D. Gilligan,Jorge A. Garcia,Chester Kao,Emily Noelle Kinsey,Patrick Healy,Julie Kephart,Michael R. Harrison,Sundhar Ramalingam,Andrew J. Armstrong,Daniel J. George,Brian I. Rini,Tian Zhang,Moshe Chaim Ornstein

Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.

2020

648Background: Ipilimumab & nivolumab (I+N) followed by nivolumab maintenance is approved as front-line therapy for intermediate and poor-risk metastatic renal cell carcinoma (mRCC). Bone metastase...

Keywords:

Pathology
Oncology
Nivolumab
Ipilimumab
Internal medicine
Renal cell carcinoma
Medicine
retrospective analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations